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ABSTRACT
Objective To assess whether patients with aortic valve 
stenosis (AS) with elevated lipoprotein(a) (Lp(a)) are 
characterised by increased valvular calcification activity 
compared with those with low Lp(a).
Methods We performed 18F- sodium fluoride (18F- 
NaF) positron emission tomography/CT in patients with 
mild to moderate AS (peak aortic jet velocity between 
2 and 4 m/s) and high versus low Lp(a) (>50 mg/dL 
vs <50 mg/dL, respectively). Subjects were matched 
according to age, gender, peak aortic jet velocity and 
valve morphology. We used a target to background ratio 
with the most diseased segment approach to compare 
18F- NaF uptake.
Results 52 individuals (26 matched pairs) were 
included in the analysis. The mean age was 66.4±5.5 
years, 44 (84.6%) were men, and the mean aortic valve 
velocity was 2.80±0.49 m/s. The median Lp(a) was 79 
(64–117) mg/dL and 7 (5–11) mg/dL in the high and 
low Lp(a) groups, respectively. Systolic blood pressure 
and low- density- lipoprotein cholesterol (corrected for 
Lp(a)) were significantly higher in the low Lp(a) group 
(141±12 mm Hg vs 128±12 mm Hg, 2.5±1.1 mmol/L 
vs 1.9±0.8 mmol/L). We found no difference in valvular 
18F- NaF uptake between the high and low Lp(a) groups 
(3.02±1.26 vs 3.05±0.96, p=0.902). Linear regression 
analysis showed valvular calcium score to be the only 
significant determinant of valvular 18F- NaF uptake 
(β=0.63; 95% CI 0.38 to 0.88 per 1000 Agatston unit 
increase, p<0.001). Lp(a) was not associated with 18F- 
NaF uptake (β=0.17; 95% CI −0.44 to 0.88, p=0.305 
for the high Lp(a) group).
Conclusion Among patients with mild to moderate 
AS, calcification activity is predominantly determined by 
established calcium burden. The results do not support 
our hypothesis that Lp(a) is associated with valvular 18F- 
NaF uptake.
INTRODUCTION
Aortic valve stenosis (AS) is one of the most 
frequent cardiovascular diseases in the Western 
world.1 Although risk factors for AS are similar 
to those for atherosclerosis, previous randomised 
trials with statins or renin- angiotensin- aldosterone 
inhibitors have not been able to influence the 
progression of AS.2 Consequently, current manage-
ment revolves around a wait- and- see approach until 
the development of severe AS warrants surgical or 
transcatheter valve replacement.3
Lipoprotein(a) (Lp(a)) has been established as 
an independent, likely causal risk factor for inci-
dent AS.4–6 Interventions aimed at lowering Lp(a), 
including proprotein convertase subtilisin/kexin 
type 9 inhibitors and apolipoprotein(a) antisense 
therapies, may be effective in delaying or preventing 
AS progression.7 However, the optimal timing of 
medical intervention in AS remains unresolved. The 
failure of previous statin trials to delay haemody-
namic progression is often attributed to initiation 
at a disease stage too advanced to be amenable for 
intervention, at which point other disease mech-
anisms drive disease progression independent of 
hypercholesterolaemia.
Valvular 18F- sodium fluoride (NaF) uptake 
assessed by positron emission tomography (PET)/
CT is robustly correlated with progression of calci-
fication.8 A recent post- hoc analysis of longitudinal 
imaging studies reported that elderly patients with 
advanced AS and higher Lp(a) levels were charac-
terised by higher valvular uptake of 18F- NaF and 
faster disease progression.9 These data support the 
concept of lowering Lp(a) in patients with estab-
lished AS to mitigate disease progression. Whether 
earlier intervention in the disease process could be 
beneficial remains unexplored.
In the current study, we hypothesised that 
patients with mild to moderate AS and significantly 
elevated Lp(a) levels (>50 mg/dL) are characterised 
by a higher degree of valvular calcification activity 
than those with lower Lp(a) levels. As such, we 
performed a matched case–control study where we 
assessed valvular calcification activity by using 18F- 
NaF PET/CT in patients with mild to moderate AS 
with higher versus lower Lp(a) levels.
METHODS
Patient selection
Participants were recruited from a biobank, 
consisting of 190 patients with mild to moderate AS 
who were previously recruited from the cardiology 
outpatient clinics of the Amsterdam University 
Medical Centers and Cardiologie Centra Neder-
land. Subjects were eligible for the study if they 
were aged between 50 and 80 years and had a peak 
aortic jet velocity between 2 and 4 m/s. Exclusion 
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m/s), aortic valve area <1.0 cm2, history of radiotherapy of the 
thorax, history of rheumatic fever, estimated glomerular filtra-
tion rate <30 mL/min, hyperparathyroidism, Paget’s disease and/
or any contraindication to PET/CT imaging. All eligible patients 
with high Lp(a) (>50 mg/dL) were asked to participate, who 
were then matched to controls with low Lp(a) levels according 
to sex, age, aortic valve morphology and peak aortic jet velocity. 
Detailed questionnaires regarding demographics, general health 
status, medical history, family history, risk factors, medication, 
blood pressure, height and weight were taken during the biobank 
study visit. Echocardiography was performed within 6 months 
of PET/CT imaging. All subjects gave written informed consent.
Laboratory measurements
Baseline blood samples including Lp(a) measurements were avail-
able from a previous biobank study. Haematology, chemistry and 
lipid panels were determined according to standardised oper-
ating procedures in a core laboratory. Low- density- lipoprotein 
cholesterol (LDL- C) was calculated using the Friedewald 
formula.10 Lp(a) was measured in all patients on serum samples 
using the kringle IV type 2 number independent Randox immu-
noassay (Randox Laboratories, UK). We corrected LDL- C for 
Lp(a) by subtracting 0.15×Lp(a) mass from the LDL- C mass.11
Echocardiography
Echocardiography was performed by the same research cardi-
ologist if not performed within 6 months prior to PET/CT 
imaging, using a dedicated echocardiography device (Vivid E95, 
GE Healthcare, Chicago, USA). The aortic valve- specific echo-
cardiogram included determination of aortic valve morphology, 
peak aortic jet velocity, transvalvular gradients and aortic valve 
area.
Image acquisition and analysis
ECG- gated 18F- NaF PET and contrast- enhanced CT angiography 
were performed using a hybrid scanner (Biograph mCT, Siemens, 
Medical Systems, Erlangen, Germany) 60 min after infusion of 
125 MBq 18F- NaF. If resting heart rate was >65 beats per minute, 
metoprolol 50 or 100 mg was administered according to clinical 
protocols. PET data were reconstructed using the Siemens Ultra 
HD reconstruction algorithm with correction for dead time, 
attenuation, random coincidences and scatter. 18F- NaF PET/CT 
images were assessed using FusionQuant V.1.20.05.14 (Cedars- 
Sinai, California, USA) using a standardised method.12 13 After 
fusing diastolic PET images with the contrast- enhanced CT, an 
en- face view was established and the PET window level adjusted 
to allow visual determination of the point of maximal specific 
valvular uptake. Automated correction for cardiac motion is 
possible and fully integrated within FusionQuant, and this was 
performed with an anatomically guided registration algorithm 
according to previously published methods.14 Briefly, a spher-
ical region of interest was drawn to include the entire aortic 
valve. A non- linear registration algorithm, radially constrained 
around the aortic valve, was used to align PET images to the 
diastolic gate. The motion- corrected gates were then summed 
to form a motion- free image containing all the PET counts. A 
three- dimensional polyhedron, 6 mm in height and contoured 
to the valve frame, was centred on this point and formed the 
volume of interest. 18F- NaF blood pool uptake was measured 
in the right atrium with a cylinder 10 mm in radius by 10 mm 
in height. Where present, pacing leads in the right atrium were 
excluded. In the control cohort, the valvular region of interest 
was centred on the valve leaflets in the z- axis, ensuring the lower 
border included the leaflet bases. The aortic valve maximum 
target to background ratio (TBRmax), a measure of the point of 
most intense 18F- NaF uptake within the volume of interest, was 
calculated as the valvular maximum standardised uptake value 
(SUVmax) divided by the atrial blood pool mean standardised 
uptake value (SUVmean). TBRmean, a measure of the average 
18F- NaF uptake in the volume of interest, was calculated as the 
valvular SUVmean divided by the blood pool SUVmean. Within 
the volume of interest, we measured the aortic valve microcalci-
fication activity (AVMA), representing the overall disease activity 
in the aortic valve and based on both the volume and intensity 
of 18F- NaF PET activity within it (similar in principle to coro-
nary microcalcification activity).15 AVMA was defined as the 
integrated activity in SUV units exceeding the corrected back-
ground blood pool mean SUV plus 2 SD (right atrium activity). 
CT aortic valve calcium (AVC) scoring according to Agatston 
methodology16 was performed using dedicated software on axial 
views ( Syngo. via, Siemens, Medical Systems). All measurements 






  Age, years 66.3±5.6 66.5±5.6 0.934*
  Male gender 22 (84.6) 22 (84.6) >0.999†
  Body mass index, kg/m2 26.9±4.5 28.5±4.2 0.316*
  Systolic blood pressure, mm Hg 128±12 141±12 <0.001*
  Diastolic blood pressure, mm Hg 79±12 85±11 0.057*
  Ischaemic heart disease 6 (23.1) 2 (7.7) 0.248‡
  Hypertension 20 (76.9) 20 (76.9) >0.999†
  Diabetes mellitus 3 (11.5) 7 (26.9) 0.291‡
  Smoking
  Never 8 (30.8) 9 (34.6) 0.872‡
  Former 12 (46.2) 13 (50)
  Active 6 (23.1) 4 (15.4)
  Use of lipid- lowering therapy 19 (73.1) 16 (61.5) 0.554†
  Use of antihypertensive(s) 18 (69.2) 19 (73.1) >0.999†
Laboratory values
  C reactive protein, mg/dL 1.1 (0.5–4.8) 1.3 (0.9–2.3) 0.521*
  Creatinine, mmol/L 87±20 87±18 0.903*
  Urea, mmol/L 6.8±2.3 7.0±2.1 0.775*
  Calcium, mmol/L 2.41±0.09 2.42±0.08 0.713*
  Phosphate, mmol/L 0.94±0.20 0.94±0.16 0.933*
  Total cholesterol, mmol/L 4.43±0.94 4.85±1.13 0.151*
  HDL- cholesterol, mmol/L 1.54±0.34 1.62±0.72 0.606*
  LDL- cholesterol, mmol/L 2.3±0.8 2.6±1.1 0.361*
  Corrected LDL- cholesterol, mmol/L 1.9±0.8 2.5±1.3 0.035*
  Triglycerides, mmol/L 1.09 (0.70–1.55) 1.29 (1.05–
2.11)
0.090§
  Lp(a), mg/dL 79 (64–112) 5 (3–10) <0.001§
Echocardiographic parameters
  Bicuspid aortic valve 5 (19.2) 5 (19.2) >0.999†
  Peak aortic jet velocity, m/s 2.77±0.55 2.83±0.42 0.689*
  Peak aortic valve gradient, mm Hg 31±13.55 30.85±10.68 0.964*
  Mean aortic valve gradient, mm Hg 17.88±8.31 17.88±6.96 0.998*
  Aortic valve area, cm2 1.77±0.64 1.62±0.42 0.345*
Data are presented as mean±SD, median (IQR) or number (percentage).
*Hypothesis tested by t-test.
†Hypothesis tested by χ2.
‡Hypothesis tested by Fisher’s exact test.
§Hypothesis tested by Mann- Whitney U test.
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were performed by experienced readers who were blinded to 
Lp(a) levels.
Statistical analysis
Data are presented as mean±SD for normally distributed vari-
ables, median with IQR for non- normally distributed variables, 
and number (percentage) for categorical variables. Between 
group testing was performed using t- test for normally distrib-
uted data, Mann- Whitney U test for non- normally distributed 
data, and χ2 or Fisher’s exact test for categorical data. Based 
on previous PET/CT studies for the assessment of arterial wall 
inflammation,17 we conservatively estimated the expected 
mean difference in valvular 18F- NaF uptake between high and 
low Lp(a) groups to be 15%. To detect this difference with 
α=0.05% and 80% power, we aimed to enrol 25 patients per 
group. Multivariable models accounting for age, sex, AVC score 
and significantly different baseline clinical parameters (p<0.05) 
were used to assess differences in valvular TBR between high 
and low Lp(a) groups. Exploratory linear regression analyses 
were performed to assess whether increasing Lp(a) within the 
high Lp(a) group was associated with active calcification, and to 
evaluate if significantly different baseline characteristics (if any) 
were related to active calcification in the low Lp(a) group. AVC 
scores were log- transformed. A two- sided p value <0.05 was 
considered statistically significant. The statistical analyses were 
performed using RStudio software (V.4.0.3; R Foundation for 
Statistical Computing, Vienna, Austria).
Patient and public involvement
Participants were not involved in determining the research ques-
tion or outcome measures, nor were they involved in recruit-
ment, design or implementation of the study. Participants were 
not asked for advice on the interpretation of results.
RESULTS
Study population
In total, 58 patients were included between February 2018 and 
October 2020. One patient withdrew prior to PET/CT imaging, 
one was excluded from further analysis due to absence of aortic 
valve calcification, and one was excluded due to a history of radi-
ation for breast cancer. In addition, we were unable to find an 
appropriate match for three participants. A total of 52 patients, 
consisting of 26 matched pairs, were included in the current 
analysis. There were no missing data. Baseline characteristics 
are listed in table 1. The mean age at the date of inclusion was 
66.0±4.2 years. The majority of participants were men (86.7%). 
Five patients in each group had bicuspid valve morphology.
Higher and lower Lp(a) groups
Higher (>50 mg/dL) and lower (<50 mg/dL) Lp(a) groups 
were well matched for age, sex, aortic valve morphology and 
peak aortic jet velocity (table 1). There was a more than tenfold 
difference in Lp(a) levels between the two groups. The median 
Lp(a) in the high group was 79 (IQR 64–117) mg/dL, compared 
with 7 (IQR 5–11) mg/dL in the lower Lp(a) group. Corrected 
LDL- C levels were significantly higher in the lower Lp(a) group 
(1.9±0.8 mmol/L in the high vs 2.5±1.1 mmol/L in the low 
Lp(a) group, p=0.035), as was systolic blood pressure (128±12 
mm Hg in the high vs 141±12 mm Hg in the low Lp(a) group, 
p<0.001).
Valvular imaging parameters
All valvular imaging parameters are listed in table 2. The CT 
AVC scores in the high and low Lp(a) groups were comparable 
between the groups (1388 Agatston units (AU) (450–2424) in the 
high vs 1173 (927–1628) AU in the low Lp(a) group, p=0.839). 
In contrast to our hypothesis, we did not observe a significant 
difference in calcification activity between the groups: the 
aortic valve TBRmax was 3.02±1.26 in the high Lp(a) group 
compared with 3.05±0.96 in the low Lp(a) group (p=0.902). 
The TBRmean showed comparable results, being 1.84±0.42 
in the high Lp(a) group vs 1.86±0.49 in the low Lp(a) group 
(p=0.863). SUV values also did not differ significantly between 
the groups nor did AVMA. Figure 1 shows the distribution of 
valvular 18F- NaF uptake in both groups.
Determinants of valvular calcification activity
In univariable regression analysis, only AVC score and male 
sex were significantly associated with valvular 18F- NaF uptake, 
whereas age, Lp(a) group, LDL- C and systolic blood pressure 
were not. Univariable analysis with only CT AVC score as deter-
minant of valvular 18F- NaF uptake showed a better fit than the 
multivariable model with age, sex, Lp(a) group, systolic blood 
pressure and corrected LDL- C (adjusted R2=0.40 for univariable 
and adjusted R2=0.35 for multivariable model). In multivariable 
linear regression analysis, the AVC score was the only determi-
nant of valvular 18F- NaF uptake (β=0.63 per 1000 increase in 
AU, 95% CI 0.38 to 0.88, p<0.001). Lp(a) group was not signifi-
cantly associated with valvular 18F- NaF uptake (β=0.17 for the 
high Lp(a) group, 95% CI −0.44 to 0.78, p=0.305), nor were 
age, sex, systolic blood pressure and corrected LDL- C (table 3). 
As an exploratory analysis, we assessed whether increasing Lp(a) 
was associated with more calcification activity in the high Lp(a) 
group only, and whether increasing blood pressure and LDL- C 
were drivers of calcification activity in the low Lp(a) group, but 
Table 2 Aortic valve imaging parameters
High Lp(a) (n=26) Low Lp(a) (n=26) P value
Aortic valve calcium score (AU) 1388 (450–2424) 1173 (927–1628) 0.839*
Aortic valve TBRmax 3.02±1.26 3.05±0.96 0.902†
Aortic valve TBRmean 1.84±0.42 1.86±0.49 0.863†
Aortic valve SUVmax 3.29±1.38 3.10±0.79 0.553†
Aortic valve SUVmean 1.87±0.40 2.00±0.64 0.399†
Aortic valve microcalcification activity 8.30±3.58 6.96±2.68 0.144†
Right atrium SUVmean 1.08±0.32 1.04±0.24 0.640†
Data are presented as mean±SD or median (IQR).
*Hypothesis tested by Mann- Whitney U test.
†Hypothesis tested by t- test.
AU, Agatston units; Lp(a), lipoprotein(a); SUVmax, maximum standardised uptake value; SUVmean, mean standardised uptake value; TBRmax, maximum target to background 
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CT AVC score remained the only predictor (online supplemental 
table 1).
DISCUSSION
In our study, we did not find a significant difference in valvular 
calcification activity, assessed with 18F- NaF PET/CT, in patients 
with mild to moderate AS and higher levels of Lp(a), compared 
with patients with lower Lp(a), when matched for age, sex and 
AS severity (figure 2). Since patients with lower Lp(a) were 
characterised by a significant increase in systolic blood pres-
sure and LDL- C, both known risk factors for AS, this may have 
obscured a potential effect of Lp(a). However, we observed the 
CT AVC score to be a highly significant predictor of valvular 
18F- NaF uptake in patients with mild to moderate AS. These 
results suggest that initiating risk factors may lose their relative 
importance in more advanced stages of AS, which seems to be 
primarily driven by valvular calcific burden.
Lp(a) and initiation of aortic valve disease
Lp(a) has been demonstrated to accumulate within the aortic 
valve leaflets of patients with AS, co- localising with calcified 
areas. Mechanistically, Lp(a) was shown to cause osteogenic 
differentiation in valvular interstitial cells via increased phos-
phorylation of several kinases such as p38 mitogen- activated 
protein kinase and glycogen synthase kinase 3 beta.18 In 
support of a potent calcification response of Lp(a), Després and 
colleagues19 observed higher valvular 18F- NaF uptake in healthy 
individuals with high Lp(a) levels of whom the majority had no 
observable calcifications on CT. In our study, valvular 18F- NaF 
uptake was approximately twofold higher than in the healthy 
Figure 1 Aortic valve calcification activity stratified by lipoprotein(a) 
(Lp(a)) group. Depicted is the calcification activity of the aortic valve, 
measured as maximum target to background ratio. This was calculated 
by dividing the valvular maximum standardised uptake by the blood 
pool mean standardised uptake value. There was no significant 
difference in calcification activity between high and low Lp(a) groups 
(3.02±1.26 vs 3.05±0.96, p=0.902).
Table 3 Linear regression analysis for valvular 18F- NaF uptake
Univariable analysis
β (95% CI) P value
Multivariable analysis
β (95% CI) P value
Intercept 2.65 (−2.65 to 6.23) 0.217
Aortic valve calcium score (per 1000 AU increase) 0.60 (0.39 to 0.81) <0.001 0.63 (0.38 to 0.88) <0.001
Age (per 10- year increase) 0.23 (−0.34 to 0.80) 0.416 −0.25 (−0.74 to 0.24) 0.305
Male sex 0.87 (0.04 to 1.70) 0.041 0.06 (−0.77 to 0.88) 0.891
High lipoprotein(a) group 0.04 (−0.59 to 0.66) 0.902 0.17 (−0.44 to 0.78) 0.573
Systolic blood pressure (per 10 mm Hg increase) 0.05 (−0.18 to 0.29) 0.639 0.10 (−0.12 to 0.32) 0.387
Corrected LDL- C (per mmol/L increase) 0.19 (−0.11 to 0.50) 0.216 −0.07 (−0.36 to 0.23) 0.648
Data are standardised coefficients (β) with 95% CI.
Adjusted R2=0.40 for the univariable analysis with aortic valve calcium score and adjusted R2=0.35 for the multivariable analysis.
AU, Agatston units; LDL- C, low- density- lipoprotein cholesterol; NaF, sodium fluoride.
Figure 2 Lp(a) has no major impact on calcification activity in 
patients with mild to moderate aortic valve stenosis. In this case–control 
study consisting of matched patients with aortic stenosis with high 
versus low Lp(a), we observed comparable calcification activity in both 
groups. Aortic valve calcium score was the only variable associated with 
18F- NaF uptake in linear regression analysis (β=0.60 per 1000 Agatston 
unit increase, 95% CI 0.39 to 0.81). Lp(a), lipoprotein(a); NaF PET/CT, 
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volunteers in the study by Després and colleagues,19 but we did 
not observe a difference in 18F- NaF uptake between patients 
with markedly elevated versus low Lp(a) levels. The discrepancy 
between these studies likely relates to the presence of established 
calcifications in the aortic valves of all our patients as opposed 
to none to negligible calcifications in Després and colleagues’19 
study. In support, CT AVC score was highly predictive of 18F- 
NaF uptake in patients with AS, implying that the contribution 
of Lp(a) is lower in more advanced disease stages of AS.20
Lp(a) and progression of established AS
In previous studies, Lp(a) has also been associated with faster 
AS progression. This was first demonstrated in a post- hoc anal-
ysis of the Aortic Stenosis Progression Observation: Measuring 
Effects of Rosuvastatin (ASTRONOMER) trial, which evaluated 
the effect of statin treatment in relatively young patients (mean 
age 58 years) with mild to moderate AS.21 Elevated Lp(a) levels 
were associated with more rapid haemodynamic AS progression 
on echocardiography over a median follow- up of 3.5 years, 
especially in younger patients (<57 years, median). These data 
suggested that as patients get older, other risk factors or disease 
mechanisms may come into play as drivers of disease progres-
sion. A subsequent post- hoc analysis of two longitudinal imaging 
studies (Scottish Aortic Stenosis and Lipid Lowering Trial, Impact 
on Regression (SALTIRE)/Ring of Fire) also supported a role of 
Lp(a) in older patients (mean age 70 years) with more advanced 
AS.9 Patients in the top Lp(a) tertile (>35 mg/dL) showed higher 
valvular 18F- NaF uptake at baseline, which associated with faster 
CT AVC score progression and a higher HR for valve replace-
ment and cardiovascular disease during follow- up, as compared 
with patients in the lower tertiles of Lp(a). Although we selected 
patients with mild to moderate AS and much higher Lp(a) levels 
in this study, we could not establish a difference in 18F- NaF 
uptake between high and low Lp(a) patients.
What drives progression of established aortic valve disease?
After strict matching for AS severity, age and sex, we did observe 
significantly higher blood pressure and LDL- C in patients with 
AS with low Lp(a). It is possible that the significantly higher 
blood pressure and LDL- C in the low Lp(a) group obscured 
the effect of Lp(a) on valvular disease activity. Nevertheless, we 
did not find associations between blood pressure, LDL- C and 
valvular 18NaF uptake. Additionally, we did not find increasing 
Lp(a) levels within the high Lp(a) group to be associated with 
increased calcification activity, nor were systolic blood pres-
sure or LDL- C associated with calcification activity in the low 
Lp(a) group. The CT AVC score was the only determinant of 
valvular calcification activity, even though we included patients 
with milder disease (peak aortic jet velocity 2.8 m/s) as compared 
with the previous imaging studies. While at odds with the Lp(a) 
literature to date, this observation is consistent with other data 
demonstrating that while traditional cardiovascular risk factors 
(eg, LDL- cholesterol) are associated with new- onset incident 
AVC, they show no relation with disease progression after 
correction for baseline AVC score.22 23 Further studies are now 
required to resolve this apparent discrepancy and also whether 
the relationship between Lp(a) and disease progression depends 
on baseline AS severity.
Study limitations
This study has several limitations that deserve consideration. 
First, our sample size was small and only able to detect a 15% 
or larger difference in valvular 18F- NaF uptake between groups. 
This modest sample size also led to the linear regression anal-
yses having more predictors than would be appropriate for the 
number of observations. However, as the beta for the high Lp(a) 
group in our linear regression analysis was only 0.17, which 
reflects 5.6% of total valvular 18F- NaF uptake, it is unlikely 
that a larger sample size would have been able to show a signif-
icant relationship between Lp(a) and calcification activity. Our 
study does not refute that Lp(a) causes calcification, which 
has been clearly established, but its effect in mild to moderate 
AS may be less pronounced than initially expected. Another 
important limitation was the higher burden of competing risk 
factors (systolic blood pressure and LDL- C) in the low Lp(a) 
group. Our study was designed to study the intrinsic impact of 
Lp(a) on 18F- NaF uptake, and therefore we applied very strict 
matching on age, sex and AS severity. Apparently, patients with 
low Lp(a) required a higher burden of alternative risk factors 
in order to achieve similar AS severity, which may have masked 
an association between Lp(a) and 18F- NaF uptake. However, the 
robust relationship between CT AVC score and valvular 18F- NaF 
uptake, combined with the absence of an association between 
Lp(a), blood pressure, LDL- C and calcification activity, makes 
this less likely. Nevertheless, we recognise that our study did 
not have sufficient power to adequately investigate the effects 
of these competing risk factors on calcification activity. Finally, 
we do not have data on the progression of valve calcification in 
the current study, which is currently a better validated endpoint 
than 18F- NaF PET.
CONCLUSION
Among patients with mild to moderate AS, we observed that 
valvular 18F- NaF uptake, a marker of calcification activity, is 
predominantly determined by established calcium burden. The 
results do not support our hypothesis that Lp(a) is associated 
with valvular 18F- NaF uptake. Nevertheless, due to the unex-
pected imbalance of competing risk factors in our study popu-
lation, we cannot rule out that Lp(a) propagates calcification 
activity in patients with AS with high Lp(a) levels. Our results 
imply that the established valvular calcific burden is the most 
Key messages
What is already known on this subject?
 ► There is substantial evidence that lipoprotein(a) (Lp(a)) is a 
causal risk factor for incident aortic valve stenosis (AS).
 ► Recent post- hoc analyses suggest that Lp(a) also accelerates 
AS progression.
What might this study add?
 ► Contrary to our hypothesis, elevated Lp(a) was not associated 
with a higher degree of calcification activity measured with 
18F- sodium fluoride positron emission tomography/CT.
 ► The only driver of calcification activity was valvular Agatston 
score.
 ► These data suggest that the association between Lp(a) and 
disease progression may depend on the severity of aortic 
stenosis as well as other competing risk factors.
How might this impact on clinical practice?
 ► The absence of an effect of Lp(a) on calcification activity in 
mild to moderate AS may require a shift in focus towards 
aggressive Lp(a)- lowering in patients with profound Lp(a) 
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important disease driver of AS. Further research evaluating 
the contribution of Lp(a) at different stages of AS severity is 
warranted.
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